Is Autolus Therapeutics plc ADR (AUTL) Stock a Good Buy for Short-term Investors?

Ulysses Smith

At the time of writing, Autolus Therapeutics plc ADR [AUTL] stock is trading at $1.65, down -0.60%. An important factor to consider is whether the stock is rising or falling in short-term value. The AUTL shares have gain 5.77% over the last week, with a monthly amount glided 19.57%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Autolus Therapeutics plc ADR [NASDAQ: AUTL] stock has seen the most recent analyst activity on November 18, 2024, when Goldman upgraded its rating to a Buy and also boosted its price target to $7.60 from $7. Previously, Redburn Atlantic upgraded its rating to Buy on November 15, 2024, and kept the price target unchanged to $13. On November 09, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $10 on the stock. Bryan Garnier initiated its recommendation with a Buy and recommended $5 as its price target on March 17, 2023. Jefferies upgraded its rating to Buy for this stock on June 14, 2021, and upped its price target to $12. In a note dated January 29, 2021, JP Morgan downgraded an Neutral rating on this stock but restated the target price of $9.

For the past year, the stock price of Autolus Therapeutics plc ADR fluctuated between $1.11 and $5.00. Currently, Wall Street analysts expect the stock to reach $8.87 within the next 12 months. Autolus Therapeutics plc ADR [NASDAQ: AUTL] shares were valued at $1.65 at the most recent close of the market. An investor can expect a potential return of 437.58% based on the average AUTL price forecast.

Analyzing the AUTL fundamentals

Gross Profit Margin for this corporation currently stands at -0.67% with Operating Profit Margin at -9.03%, Pretax Profit Margin comes in at -7.47%, and Net Profit Margin reading is -7.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.56 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.

Ratios To Look Out For

It is important to note that Autolus Therapeutics plc ADR [NASDAQ:AUTL] has a current ratio of 8.38. On the other hand, the Quick Ratio is 8.03, and the Cash Ratio is 1.82. Considering the valuation of this stock, the price to sales ratio is 14.55, the price to book ratio is 1.69.

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.